Publicaciones en colaboración con investigadores/as de University of Groningen (7)

2024

  1. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    The Lancet Regional Health - Europe, Vol. 38

  2. Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study

    Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306

2023

  1. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

2022

  1. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

    JTO Clinical and Research Reports, Vol. 3, Núm. 9

  2. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

    ESMO Open, Vol. 7, Núm. 2

  3. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

    Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178

2017

  1. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426